Candonilimab
- Generic Name
- Candonilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2394841-59-7
- Unique Ingredient Identifier
- 6FYG1DS4NW
- Background
Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).
- Indication
用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Akeso
- Target Recruit Count
- 6
- Registration Number
- NCT04547101
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 34
- Registration Number
- NCT04220307
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath